Cancer vaccines: Between the idea and the reality

Nature Reviews Immunology

Volumn 3, Issue 8, 2003, Pages 630-641

  Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; IMMUNOLOGICAL ADJUVANT; MELACINE; MUCIN 1; UNCLASSIFIED DRUG; DNA VACCINE; TUMOR ANTIGEN;

AGE; AUTOIMMUNITY; CANCER PREVENTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; MEMORY CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, DNA;

EID: 0141720783     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1150     Document Type: Review

References (164)

1. Jeriner, E. in Sampson Low (Soho, London, 1798).
2. Andre, F. E. Vaccinology past achievements, present roadblocks and future promises. Vaccine 21, 593-595 (2003).
3. Ward, S. et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 351-357 (2002).
4. Jaffee, E. M. et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156 (2001).
5. Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002).
6. Ludewig, B. et al. M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795-804 (2000). This paper shows data from transgenic mice that a dendritic cell (DC)-based vaccine with antigens that are expressed by tumours, as well as by various normal tissues, can cause fatal autoimmune diseases, such as autoimmune diabetes, arteritis and myocarditis.
7. + T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982-2987 (1999).
8. van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001).
9. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002). This paper convincingly illustrates the power of tumour-specific T cells directed against self/differentiation antigens that are overexpressed by tumours. Adoptive transfer of these cells into metastatic melanoma patients resulted in the regression of melanoma, but also in the onset of vitiligo - autoimmune melanocyte destruction.
10. Heimberger, A. B. et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50, 158-166 (2002).
11. Pupa, S. M. et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther. 8, 75-79 (2001).
12. Soares, M. M., Mehta, V. & Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563 (2001). This paper shows the importance of not only the right antigen but also the right adjuvant for an effective antitumour vaccine. Mucin 1 peptide was administered in three different vaccine preparations. All induced immune responses, but only one (DCs loaded with mucin 1) induced tumour rejection. The effective immune response did not cause autoimmunity in mucin 1-transgenic mice.
13. Van Der Bruggen, P. et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188, 51-64 (2002).
14. Henderson, R. A. & Finn, O. J. Human tumor antigens are ready to fly. Adv. Immunol. 62, 217-256 (1996).
15. Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002).
16. Apostolopoulos, V., Pietersz, G. A. & McKenzie, I. F. MUC1 and breast cancer. Curr. Opin. Mol. Ther. 1, 98-103 (1999).
17. H) cells, can elicit in patients with cancer, immunity to the peptides, as well as the whole protein, and provoke endogenous immune responses that lead to epitope spreading.
18. Chomez, P. et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544-5551 (2001).
19. Tanaka, Y., Amos, K. D., Fleming, T. P., Eberlein, T. J. & Goedegebuure, P. S. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Surgery 133, 74-80 (2003).
20. Schlom, J. et al. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res. Treat. 38, 27-39 (1996).
21. + T-cell responses. Cyclin B1 is aberrantly expressed by many cancers.
22. Jager, D. et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res. 59, 6197-6204 (1999).
23. Nestle, F. O. Vaccines and melanoma. Clin. Exp. Dermatol. 27, 597-601 (2002).
24. Srivastava, P. K. Immunotherapy of human cancer: lessons from mice. Nature Immunol. 1, 363-366 (2000).
25. Gendler, S. J. & Mukherjee, P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol. Med. 7, 471-475 (2001).
26. Greiner, J. W., Zeytin, H., Anver, M. R. & Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumours in the absence of autoimmunity. Cancer Res. 62, 6944-6951 (2002). This paper shows the efficacy of a carcinoembryonic antigen (CEA) vaccine against spontaneous intestinal tumours in genetically predisposed mice. The vaccine generated a strong anti-CEA response that reduced the tumour incidence and increased overall survival without causing autoimmunity.
27. Meng, W. S. et al. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 61, 8782-8786 (2001).
28. Ranieri, E. et al. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol. Invest. 29, 121-125 (2000).
29. Butterfield, L. H. et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9, 998-1008 (2003).
30. Salgaller, M. L. & Lodge, P. A. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68, 122-138 (1998).
31. Medzhitov, R. CpG DNA: security code for host defense. Nature Immunol. 2, 15-16 (2001).
32. Krug, A. et al. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 170, 3468-3477 (2003).
33. Janeway, C. A., Jr & Medzhitov, R. Lipoproteins take their toll on the host. Curr. Biol. 9, R879-R882 (1999).
34. H1 responses. J. Immunol. 170, 194-200 (2003).
35. Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243-246 (1995).
36. Gupta, R. K., Singh, M. & O'Hagan, D. T. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 32, 225-246 (1998).
37. H immune response without adjuvant. Eur. J. Immunol. 28, 1401-1407 (1998).
38. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344, 873-875 (1990).
39. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20, 395-425 (2002).
40. Eriksson, K. & Holmgren, J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 14, 666-672 (2002).
41. Cook, D. N. et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12, 495-503 (2000).
42. Csencsits, K. L., Jutila, M. A. & Pascual, D. W. Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur. J. Immunol. 32, 3029-3039 (2002).
43. Williamson, E., Bilsborough, J. M. & Viney, J. L. Regulation of mucosal dendritic cell function by receptor activator of NF-κB (RANK/RANK ligand interactions: impact on tolerance induction. J. Immunol. 169, 3606-3612 (2002).
44. Medzhitov, R. & Janeway, C., Jr. The Toll receptor family and microbial recognition. Trends Microbiol. 8, 452-456 (2000).
45. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu, Rev. Immunol. 7, 145-173 (1989).
46. + patients with renal cell carcinoma or melanoma. J. Exp. Med. 196, 619-628 (2002).
47. Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M. & Levy, R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92, 1184-1190 (1998).
48. Vogel, C. et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37, S25-S29 (2001).
49. Riethmuller, G. et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343, 1177-1183 (1994).
50. Hsu, F. J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135 (1997).
51. Livingston, P. O. et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl Acad. Sci. USA 84, 2911-2915 (1987).
52. Parmiani, G. et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94, 805-818 (2002).
53. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
54. Zinkernagel, R. M. On differences between immunity and immunological memory. Curr. Opin. Immunol. 14, 523-536 (2002).
55. Sallusto, F., Langenkamp, A., Geginat, J. & Lanzavecchia, A. Functional subsets of memory T cells identified by CCR7 expression. Curr. Top. Microbiol. Immunol. 251, 167-171 (2000).
56. Harrington, L. E., Galvan, M., Baum, L. G. Altman, J. D. & Ahmed, R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J. Exp. Med. 191, 1241-1246 (2000).
57. + T cells generated depends on the nature of the initial nonspecific stimulation. Eur. J. Immunol. 32, 1541-1549 (2002).
58. Xiang, R., Lode, H. N., Gillies, S. D. & Reisfeld, R. A. T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 163, 3676-3683 (1999).
59. + T cells in melanoma patients receiving interleukin 12. Cancer Res. 60, 3559-3568 (2000).
60. Feuerer, M. et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nature Mad. 7, 452-458 (2001).
61. + T cells. Curr. Opin. Immunol. 10, 444-449 (1998).
62. van der Burg, S. H. et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol. 31, 146-155 (2001).
63. + T cell to a fully functional tumor killer cell. Cancer Res. 62, 6438-6441 (2002).
64. Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 4, 225-234 (2003).
65. + retrovirus infection. Virology 299, 8-19 (2002).
66. Kapasi, Z. F., Murali-Krishna, K., McRae, M. L. & Ahmed, R. Defective generation but normal maintenance of memory T cells in old mice. Eur. J. Immunol. 32, 1567-1573 (2002).
67. Khare, V., Sodhi, A. & Singh, S. M. Age-dependent alterations in the tumoricidal functions of tumor-associated macrophages. Tumour Biol. 20, 30-43 (1999).
68. Lu, Y. F. & Cerny, J. Repertoire of antibody response in bone marrow and the memory response are differentially affected in aging mice. J. Immunol. 169, 4920-4927 (2002).
69. + T cells. J. Immunol. 169, 5021-5027 (2002).
70. Miller, R. A. & Chrisp, C. T cell subset patterns that predict resistance to spontaneous lymphoma, mammary adenocarcinoma, and fibrosarcoma in mice. J. Immunol. 169, 1619-1625 (2002). This and other papers by the first author focus on age-induced changes in the immune system that contribute to carcinogenesis and could affect the success of cancer vaccines.
71. Provinciali, M., Smoriesi, A., Donnini, A., Bartozzi, B. & Amici. A Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21, 843-848 (2003). This paper shows a clear difference in the response of young versus old mice to a HER2/NEU-containing cancer vaccine and the difference in the immune-effector mechanisms that are generated.
72. Bansal-Pakala, P. & Croft, M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169, 5005-5009 (2002).
73. Egen, J. G., Kuhns, M. S. & Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3, 611-618 (2002).
74. H1 differentiation in aged BALB/c mice. J. Leukoc. Biol. 72, 447-454 (2002).
75. Geiger, J. D. et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61, 8513-6519 (2001).
76. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
77. Ishida, T., Oyama, T., Carbone, D. P. & Gabrilovich, D. I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. 161, 4842-4851 (1998).
78. + hematopoietic progenitors. Eur. Urol. 39, S37-S40 (2001).
79. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798 (1992). The original paper that describes tumour-induced suppression of T cells in mice with tumours.
80. Finke, J., Ferrone, S., Frey, A., Mufson, A. & Ochoa, A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today. 20, 158-160 (1999).
81. Garcia-Hernandez, M. L., Hernandez-Pando, R., Ganglio, P. & Berumen, J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunol. 105, 231-243 (2002).
82. + T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-β: implications for dendritic cell immunization against cancer. Clin. Immunol. 102, 96-105 (2002).
83. Skinnider, B. F. & Mak, T. W. The role of cytokines in classical Hodgkin lymphoma. Blood 99, 4283-4297 (2002).
84. Friberg, M. et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151-155 (2002).
85. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
86. Schmielau, J. & Finn, O. J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underfiling mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756-4760 (2001).
87. Ahlers, J. D. et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl Acad. Sci. USA 99, 13020-13025 (2002).
88. Gabdlovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
89. Meidenbauer, N., Gooding, W., Spitler, L., Harris, D. & Whiteside, T. L. Recovery of ζ-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br. J. Cancer 86, 168-178 (2002).
90. Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
91. + immunoregulatory cells. J. Immunol. 167, 1137-1140 (2001).
92. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32, 3267-3275 (2002).
93. Mitchell, M. S. et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48, 5883-5893 (1988).
94. Morton, D. L. et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 236, 438-449 (2002).
95. Bystryn, J. C. et al. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61, 1065-1070 (1988).
96. Miller, K. et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75, 495-502 (1995).
97. Mitchell, M. S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623-635 (1998).
98. Berd, D., Sato, T., Cohn, H., Maguire, H. C., Jr & Mastrangelo, M. J. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int. J. Cancer 94, 531-539 (2001).
99. Mach, N. & Dranoff, G. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12, 571-575 (2000).
100. Belli, F. et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002).
101. Salgia, R. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
102. Nestle, F. O., Banchereau, J. & Hart, D. Dendritic cells: on the move from bench to bedside. Nature Med. 7, 761-765 (2001).
103. Celluzzi, C. M. & Falo, L. D., Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160, 3081-3085 (1998).
104. Nouri-Shirazi, M. et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 165, 3797-3803 (2000).
105. Chang, A. E. et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021-1032 (2002).
106. Heiser, A. et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166, 2953-2960 (2001).
107. Nair, S. K. et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235, 540-549 (2002).
108. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K. & Falo, L. D., Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2, 1122-1128 (1996).
109. Whiteside, T. L., Gambotto, A., Albers, A., Stanson, J. & Cohen, E. P. Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. Proc. Natl Acad. Sci. USA 99, 9415-9420 (2002).
110. Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417 (2002).
111. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J. & Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-304 (1996).
112. Khleif, S. N. et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. 22, 155-165 (1999).
113. Massaia, M. et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673-683 (1999).
114. van Driel, W. J. et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952 (1999).
115. Brossart, P. et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102-3108 (2000).
116. Marshall, J. L. et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3973 (2000).
117. + progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
118. Schuler-Thurner, B. et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288 (2002).
119. Knutson, K. L., Schiffman, K. & Disis, M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484 (2001).
120. van der Burg, S. H. et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8, 1019-1027 (2002).
121. Marchand, M. et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39, 70-77 (2003).
122. Finn, O. J. & Fomi, G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14, 172-177 (2002).
123. Schultz, J. Success of vaccine offers promise of cervical cancer prevention. J. Natl Cancer Inst. 95, 102-104 (2003).
124. Welters, M. J. et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63, 636-641 (2003).
125. Plummer, M. & Franceschi, S. Strategies for HPV prevention. Virus Res. 89, 285-293 (2002).
126. Huang, K. & Lin, S. Nationwide vaccination: a success story in Taiwan. Vaccine 18, S35-S38 (2000).
127. Viviani, S. et al. Hepatitis B vaccinaton in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17, 2946-2950 (1999).
128. Lollini, P. L. et al. Immunoprevention of colorectal cancer: a future possibility? Gastroenterol. Clin. North Am. 31, 1001-1014 (2002).
129. Lollini, P. L. & Forni, G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. Immunother. 51, 409-416 (2002).
130. Muderspach, L. et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6, 3406-3416 (2000).
131. Finn, O. J. et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61-89 (1995).
132. Domenech, N., Henderson, R. A. & Finn, O. J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155, 4766-4774 (1995).
133. + T cells. Cancer Res. 58, 5066-5070 (1998).
134. Hiltbold, E. M., Alter, M. D., Ciborowski, P. & Finn, O. J. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. 194, 143-149 (1999).
135. H cells.
136. Apostolopoulos, V., Karanikas V., Haurum, J. S. & McKenzie, I. F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159, 5211-5218 (1997).
137. Brossart, P. et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309-4317 (1999).
138. Lees, C. J. et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19, 158-162 (2000).
139. Mukherjee, P. et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J. Immunol. 165, 3451-3460 (2000).
140. Pecher, G. & Finn, O. J. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl Acad. Sci. USA 93, 1699-1704 (1996).
141. Barratt-Boyes, S. M., Vlad, A. & Finn, O. J. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin. Cancer Res. 5, 1918-1924 (1999).
142. Carr-Brendel, V. et al. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res. 60, 2435-2443 (2000).
143. Grosenbach, D. W., Barrientos, J. C., Schlom, J. & Hodge, J. W. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61, 4497-4505 (2001).
144. Xiang, R. et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer Res. 7, S856-S864 (2001).
145. Cole, D. J. et al. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum. Gene Ther. 7, 1381-1394 (1996).
146. Nanni, P. et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 1195-1205 (2001).
147. Timmerman, J. M. & Levy, R. The history of the development of vaccines for the treatment of lymphoma. Clin. Lymphoma 1, 129-139; discussion 140 (2000).
148. Hruban, R. H. et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586 (2001).
149. Nelson, W. G. et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. NY Acad. Sci. 952, 135-144 (2001).
150. Burgart, L. J. Colorectal polyps and other precursor lesions. Need for an expanded view. Gastroenterol. Clin. North Am. 31, 959-970 (2002).
151. Pfau, P. & Chak, A. Detection of preinvasive cancer cells: early-warning changes in precancerous epithelial cells can now be spotted in situ and endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattered spectroscopy. Gastrointest. Endosc. 54, 414-416 (2001).
152. Kauff, N. D. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346, 1609-1615 (2002).
153. Meijers-Heijboer, H. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 159-164 (2001).
154. Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622 (2002).
155. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77-84 (1999).
156. Pennisi, V. R. & Capozzi, A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast. Surg. 18, 15-21 (1989).
157. Stefanek, M., Hartmann, L. & Nelson, W. Risk-reduction mastectomy: clinical issues and research needs. J. Natl Cancer Inst. 93, 1297-1306 (2001).
158. Disis, M. L. et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99, 2845-2850 (2002).
159. Whitcomb, D. C. Genetic predispositions to acute and chronic pancreatitis. Med. Clin. North Am. 84, 531-547 (2000).
160. Lowenfels, A. B. et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl Cancer Inst. 89, 442-446 (1997).
161. Lowenfels, A. B., Maisonneuve, P., Whitcomb, D. C., Lerch, M. M. & DiMagno, E. P. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 286, 169-170 (2001).
162. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
163. Vavasseur, F. et al. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur. J. Biochem. 222, 415-424 (1994).
164. Li, A. et al. Comparative study for histology, proliferative activity, glycoproteins, and p53 protein between old and recent colorectal adenomas in Japan. Cancer Lett. 170, 45-52 (2001).